Objectives: To describe the virological and pharmacological outcomes of three different recommended oncedaily first-line regimens in a cross-sectional analysis within an observational cohort using ultra-sensitive HIV quantification.
Introduction
The objective of combined antiretroviral therapy (cART) is to reach and maintain plasma virological suppression ,50 copies/mL. 1 The choice of first-line cART regimens recommended by the US Department of Health and Human Services guidelines is based on the results of randomized clinical trials. We can reasonably hypothesize that the results obtained in the context of a clinical cohort could be different from those observed in randomized clinical trials. These differences could result from dissimilarities between patient characteristics and/or to less stringent clinical and biological follow-up, which might play a role in the level of adherence to therapy.
Upgraded commercial assays for HIV quantification are now able to detect viral loads (VLs) ,50 copies/mL, such as the COBAS AmpliPrep/COBAS TaqMan HIV-1 v2.0 assay, with a limit of detection of 20 copies/mL. Even if the relevance in the clinical setting of residual viraemia between 20 and 50 copies/mL is still a matter for debate, 2 -5 data are needed using this lower threshold. Moreover, none of the clinical trials assessing first-line regimens has used ultrasensitive VL testing with a threshold of 1 copy/mL.
In randomized clinical trials, adherence is mostly assessed by self-report. Therapeutic drug monitoring is either not systematic or is performed only in patients experiencing virological failure.
Therefore, few studies are available combining data on the efficacy of different recommended first-line regimens assessed using an ultrasensitive HIV quantification assay with a threshold of 20 copies/mL or 1 copy/mL and the measurement of drug plasma concentrations.
The aim of this study was to describe the virological and pharmacological outcomes of three different recommended once-daily first-line regimens, including efavirenz, darunavir or atazanavir as the third agent of the cART and using ultrasensitive HIV quantification in a cross-sectional analysis within an observational cohort.
Patients and methods

Study population
This was an observational, non-comparative, single-centre study. We enrolled all antiretroviral-naive HIV-infected patients initiating care at Bichat-Claude Bernard clinical centre, Paris, France, who received tenofovir/emtricitabine with efavirenz, darunavir/ritonavir or atazanavir/ ritonavir as a first-line regimen at the standard once-daily dose between 1 November 2010 and 30 June 2012. Patients treated during a primary HIV infection were excluded. All the patients enrolled in this study gave their written consent to have their medical chart recorded in the electronic medical record system Nadis w (Fé dialis Mé dica, Marly Le Roi, France, CNIL number: 1171457 24 May 2006), designed for the medical follow-up of HIV-infected patients.
Virological and pharmacological analyses
Virological and pharmacological analyses were performed at Week (W) 4, W12, W24, W36 and W48.
Plasma HIV-1 RNA VL was measured at the virology laboratory of Bichat-Claude Bernard hospital using the COBAS w AmpliPrep/COBAS w TaqMan w HIV-1 Test, version 2.0 (Roche Diagnostics, Branchburg, NJ, USA), with a lower quantification limit of 20 copies/mL. A detectable signal on the quantification assay displayed a VL between 1 and 20 copies/mL and the VL was considered to be ,1 copy/mL when the viral target was not detected by the assay.
Drug plasma concentrations were measured using ultra-performance liquid chromatography combined with tandem mass spectrometry (Waters Corporation Milford, MA, USA). 6 Efavirenz, darunavir and atazanavir concentrations at 24 h (C 24 ) were interpreted according to the respective usual effective cut-offs of 1000 ng/mL, 550 ng/mL and 150 ng/mL as previously mentioned in the guidelines. 1 
Genotypic resistance tests
Bulk sequencing of protease, reverse transcriptase and gp120 V3 loop regions was performed at baseline and during follow-up in patients experiencing virological failure. Genotypic resistance tests were performed and interpreted according to the sequencing procedures, primer sequences and resistance algorithm described at www.hivfrenchresistance.org.
At baseline, drug-resistance mutations (DRMs) were identified according to the 2009 WHO update surveillance DRM list. 7 
Statistical analyses
Continuous variables were expressed as median and IQR, and categorical variables were expressed as percentages. To compare variables between patients in the different arms, or between baseline and W48, the MannWhitney/Wilcoxon test or Fisher's exact test was used, with a 0.05 significance level. Analyses were performed with StatEL statistical software (StatEL Base, www.adscience.eu).
Results
Patients' baseline characteristics
A total of 168 patients were enrolled, with a median age of 38 years (IQR ¼ 32-44 years), and 51 (30%) were women. Of these, 60 patients (36%) received efavirenz, 81 (48%) darunavir/ritonavir and 27 (16%) atazanavir/ritonavir (Table 1) . Overall, the median plasma VL was 4.95 log 10 copies/mL (IQR 4.40 -5.34 log 10 copies/mL) and 76 (45%) patients had a VL .100 000 copies/mL. The median CD4 cell count was 353 cells/mm 3 (IQR 214-442 cells/mm 3 ) and 38 (24%) patients had a CD4 count ,200 cells/mm 3 . There were 94/165 (57%) patients infected with non-B HIV-1, including 64 (68%) with CRF02_AG. A total of 113/142 (80%) patients exhibited R5 viruses and 12 (7%) were coinfected with hepatitis B or C virus. Five patients had viruses harbouring DRMs, leading to a prevalence of transmitted drug resistance of 3.0% (95% CI 0.4% -5.6%).
The baseline characteristics of the three groups of patients were not similar. Thus, starting an efavirenz-based regimen was significantly more frequent in patients belonging to the risk transmission group of men who have sex with men (P, 0.0001) and significantly less frequent in women (P, 0.0001). Starting a darunavir-based regimen was significantly more frequent in patients with a VL .100000 copies/mL (P ¼0.022) and in patients with a CD4 count ,200 cells/mm 3 (P ¼ 0.0008). Starting an atazanavir-based regimen was significantly more common in non-B HIV-1-infected patients (P ¼ 0.025) and in patients of black ethnicity (P¼ 0.006).
Virological and immunological responses
At W48, 15 (9%) of the patients had discontinued their first-line regimen; 9 (15%) in the efavirenz group, 5 (6%) in the darunavir/ritonavir group and 1 (4%) in the atazanavir/ritonavir group. In most of these cases (n ¼ 11), patients who discontinued their regimen exhibited a VL ,20 copies/mL and switched for reasons of tolerance or simplification. The proportion of patients who discontinued their first-line regimen was higher in the efavirenz group (P ¼ 0.04). Data were missing at W48 for 6, 9 and 2 patients in the efavirenz, darunavir/ritonavir and atazanavir/ritonavir groups, respectively. At W48, among the 153 patients still receiving their first-line regimen, 89%, 85% and 88% patients had a VL ,50 copies/mL and 69%, 73% and 79% had a VL ,20 copies/mL in the efavirenz, darunavir/ritonavir and atazanavir/ritonavir groups, respectively ( Figure 1 ). Ultrasensitive VL results at W48 showed that 45%, 48% and 54% of the patients had no detectable VL signal (,1 copy/mL) in the efavirenz, darunavir/ritonavir and atazanavir/ritonavir groups, respectively (Figure 1) . Among patients achieving a VL ,20 copies/mL at W48, 65%, 67% and 68% had no detectable VL signal in the efavirenz, darunavir/ritonavir and atazanavir/ritonavir groups, respectively.
Patients with a detectable VL signal, i.e. between 1 and 20 copies/mL, at W48 had a significantly higher baseline VL than patients with no detectable signal (5.08 versus 4.65 log 10 copies/mL, P ¼ 0.0001). Among patients with a baseline VL ≤100 000 copies/mL achieving a VL ,20 copies/mL at W48, 15/21 (71%), 20/24 (83%) and 8/11 (73%) had a VL ,1 copy/mL Charpentier et al.
at W48 in the efavirenz, darunavir/ritonavir and atazanavir/ ritonavir groups, respectively. Among patients with a baseline VL .100 000 copies/mL achieving a VL ,20 copies/mL at W48, 4/8 (50%), 9/20 (45%) and 3/6 (50%) had a VL ,1 copy/mL at W48 in the efavirenz, darunavir/ritonavir and atazanavir/ritonavir groups, respectively.
Genotypic resistance tests were performed in patients with a VL .50 copies/mL at W36 or W48. The median VL was 159 copies/mL (IQR ¼ 74 -1147 copies/mL). Among the 29 eligible patients (7 in the efavirenz group, 17 in the darunavir/ritonavir group and 5 in the atazanavir/ritonavir group), plasma specimens were available for 22. Due to low plasma viraemia, genotypic results tests were obtained in only seven (32%), showing six wildtype viruses and selection of the M184V mutation in one case enrolled in the darunavir/ritonavir group.
The median increase in CD4 cell count from baseline to W48 was 198/mm 3 Charpentier et al.
and atazanavir C 24 measurements were above the respective effective cut-offs ( Figure 2 ). The interpatient variability in C 24 was higher with the darunavir/ritonavir once-daily regimen [coefficient of variation (CV) 171%] than in the efavirenz (CV 91%) and atazanavir/ritonavir (CV 133%) groups. The intrapatient variability of plasma drug concentrations was 29% in the efavirenz group, 41% in the darunavir/ ritonavir group and 55% in the atazanavir/ritonavir group.
Regarding all the paired HIV VL and drug plasma concentrations data available at W36 and W48 in the three arms of the study (n¼ 149), the proportion of patients with adequate plasma drug concentrations was 92% (121/131) and 78% (14/18) in patients with a VL ,50 copies/mL and in those with a VL .50 copies/mL, respectively (P ¼ 0.07). At the threshold of 1 copy/mL, 91% and 90% of patients displayed plasma drug concentrations above their respective cut-off in patients with a VL ,1 copy/mL and in those with a VL .1 copy/mL, respectively.
Discussion
In this observational cohort of 168 HIV-infected patients initiating one of three once-daily first-line recommended regimens, 45%, First-line regimen response in clinical cohort 2823 JAC 48% and 54% of patients had a VL ,1 copy/mL at W48 in the efavirenz, darunavir/ritonavir and atazanavir/ritonavir groups. A baseline VL .100 000 copies/mL was associated with a higher risk of displaying a detectable VL signal at W48. The first finding of our study is that patients' characteristics were not similar with respect to the third agent they received (efavirenz, darunavir or atazanavir). Differences were observed regarding: (i) gender, with a low proportion of females receiving efavirenz; (ii) ethnic group; and (iii) VL level. Indeed, a higher proportion of patients with more advanced HIV infection, i.e. with a VL .100 000 copies/mL and a CD4 count ,200 cells/mm 3 , were receiving darunavir. Therefore, the choice of the third agent is clearly not random, preventing any reliable comparison between the different drugs. These findings showed that, in clinical practice, the choice of the first-line regimen is significantly influenced by physicians' preferences, their acquired concepts and also the clinical and demographic characteristics of the patient. A previous study has reported such a trend towards individualized cART influenced by the physician's knowledge and the patient's characteristics. 8 That study compared patients on first-line treatment receiving efavirenz, atazanavir/ritonavir or lopinavir/ritonavir with different backbones of nucleoside reverse transcriptase inhibitors. 8 The rates of virological suppression observed at W48 in the randomized clinical trials were: (i) between 81% and 84% in the efavirenz arms of the STARTMRK, GS-0102, STaR and SINGLE trials; 9 -12 (ii) 84% in the darunavir arm of the ARTEMIS trial; 13 and (iii) 78% and 87% in the atazanavir arms of the CASTLE and GS-0103 trials, respectively. 14, 15 In our study, we observed similar results, with 89%, 85% and 88% of patients exhibiting a plasma VL ,50 copies/mL at W48 in the efavirenz, darunavir/ritonavir and atazanavir/ritonavir groups, respectively. Therefore, despite the non-randomization and patient bias, similar results were obtained in a clinical cohort. Previous studies showed similar results of cART efficacy between randomized trials and observational cohorts, 16, 17 although these assessed different cARTs from those in our study.
In this clinical cohort, adequate plasma drug concentrations were observed in a high proportion of patients, strongly suggesting good treatment adherence whatever the third agent used. There is a trend of a higher proportion of patients with adequate plasma drug concentrations in patients with a VL ,50 copies/mL than in those with a VL .50 copies/mL (P ¼ 0.07). We can hypothesize that the limited sample size of patients with a VL .50 copies/mL or with a C 24 below the effective cut-off leads to a lack of statistical power for this analysis. No difference was observed in the proportion of patients with adequate plasma drug concentrations between patients with a VL ,1 copy/mL and those with a VL .1 copy/mL, 91% and 90%, respectively.
In our study the proportion of patients exhibiting a VL between 20 and 50 copies/mL was not significantly different between the three groups: 20% with efavirenz, 12% with darunavir/ritonavir and 9% with atazanavir/ritonavir. It is now well known that the use of more sensitive VL assays has demonstrated VL values between 20 and 50 copies/mL in some patients. 2 -5,18 Previous studies reported a prevalence of 25.3% of patients successfully treated with cART who displayed a plasma VL ranging from 20 to 50 copies/mL, 18 a range similar to what was observed in our study. The clinical relevance of this residual viraemia is still under discussion; however, it has been reported to be associated with an increased risk of virological failure 2, 3 and is also associated with chronic immune activation. 19, 20 In our study, 40% of patients who displayed on average a VL ,50 copies/mL at W48 did not reach a VL ,1 copy/mL. The probability of reaching a VL ,1 copy/mL at W48 did not differ according to the regimen or the drug concentration. We can hypothesize that using a longer follow-up period, for example to W96, would lead to a higher proportion of patients reaching a VL ,1 copy/mL. Unlike previous studies, 21, 22 we did not find any difference in the proportion of patients with a detectable VL signal at W48 between those treated with a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor. However, the sample size was small and the study was not designed for this objective. The only factor associated with a detectable VL signal at W48 was a baseline VL .100 000 copies/mL. Indeed, patients with a detectable VL signal at W48 had a significantly higher baseline VL than patients with no VL signal (5.08 versus 4.65 log 10 copies/mL, P ¼ 0.0001). It is obviously more difficult to obtain an undetectable VL when initiating cART with a higher baseline VL. Several randomized clinical trials have shown a lower rate of virological response and an increased risk of resistance selection in patients with high pre-therapeutic VLs (i.e. .100 000 copies/mL). 23, 24 In this study, enrolling 168 HIV-infected patients who started on three different once-daily recommended first-line regimens in a clinical care setting, the choice of the drug regimen was related to the patient's characteristics, such as demographic criteria and immunovirological status. The proportion of patients reaching a VL ,1 copy/mL at W48 was in a similar range among the three regimens and was not found to be associated with drug concentration. The current threshold of virological suppression used still remains 50 copies/mL and randomized prospective studies are needed to assess the clinical relevance to lowering the threshold of virological suppression.
